The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
The contents of these questions are taken from the Galderma Pre-Board Webinar. The Pre-Board Webinar is now an online course. For details, go to https://www.galdermausa.com/Our-Commitment/PreBoard-Webinar.aspx.
What are the characteristics
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
b) Chronic cutaneous lupus erythematosus
c) Subacute cutaneous lupus erythematosus
d) Neonatal lupus erythematosus
e) Drug-induced lupus erythematosus
2. Which of the following is associated with this condition?
a) Streptococcus pyogenes
b) Rheumatoid arthritis
c) Clostridium perfringens
d) Spider bite
e) Coeliac sprue
{{pagebreak}}
BOARD REVIEW ANSWERS
1. This antinuclear antibody (ANA) is most characteristic of:
a) Acute cutaneous lupus erythematosus
This slide shows a “rim” pattern ANA which is associated with autoantibodies to double-stranded DNA. These antibodies and the ANA pattern are relatively specific for systemic lupus erythematosus (SLE) and are associated with more severe forms of SLE, such as acute cutaneous lupus erythematosus.
References
Sontheimer RD, Deng JS, Gilliam JN. Antinuclear and anticytoplasmic antibodies. Concepts and misconceptions. J Am Acad Dermatol. 1983;9(3):335-343.
Sontheimer RD, McCauliffe DP, Zappi E, Targoff I. Antinuclear antibodies: clinical correlations and biologic significance. Adv Dermatol. 1992;7:3-52.
2. Which of the following is associated with this condition?
b) Rheumatoid arthritis
Pyoderma gangrenosum is associated with a number of other disorders including ulcerative colitis, regional enteritis, rheumatoid arthritis, infectious hepatitis, leukemia, myeloma, benign monoclonal gammopathy, Wegener granulomatosis, and Behçet syndrome. There is an increased incidence of arthritis in pyoderma gangrenosum, which appears to be associated with the pyoderma gangrenosum and not some underlying disease.
Reference
Ko CB, Walton S, Wyatt EH. Pyoderma gangrenosum: associations revisited. Int J Dermatol. 1992;31(8):574-577.
Jo-David Fine, MD, MPH, FRCP, is board certified in internal medicine, dermatology, and diagnostic and laboratory immunodermatology. Dr Fine is currently professor of medicine (dermatology) and pediatrics at Vanderbilt University School of Medicine in Nashville, TN.
Ron J. Feldman, MD, PhD, is assistant professor in the department of dermatology at Emory University School of Medicine in Atlanta, GA.
Researchers aimed to review how timely recognition of clinical signs and symptoms is crucial for initiating appropriate treatment and alleviating the associated disease burden.
Researchers aimed to review how timely recognition of clinical signs and symptoms is crucial for initiating appropriate treatment and alleviating the associated disease burden.
Steven R. Feldman, MD, PhD; Sarah L. Taylor, MD, MPH, BS ; Tom Soker, MD; Matthew L. Melton, MD
This article discusses natural alternatives to conventional treatments and explains how many conventional dermatology treatments can be considered natural themselves.
This article discusses natural alternatives to conventional treatments and explains how many conventional dermatology treatments can be considered natural themselves.
In her session, “Hidradenitis Suppurativa: Novel Medical and Surgical Approaches,” Dr Alexandra Charrow illuminated novel approaches to managing hidradenitis suppurativa presented at Spring Dermatology Week 2024.
In her session, “Hidradenitis Suppurativa: Novel Medical and Surgical Approaches,” Dr Alexandra Charrow illuminated novel approaches to managing hidradenitis suppurativa presented at Spring Dermatology Week 2024.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Test your expertise in identifying risk factors for persistent pediatric atopic dermatitis and understanding the interplay between barrier dysfunction and immune dysregulation.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Assess advanced clinical reasoning in pediatric atopic dermatitis, including implications of type 2 inflammation for diagnosis, treatment timing, and systemic therapy decisions.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
Challenge your understanding of direct and indirect cytokine–nerve interactions and mechanical hypersensitivity of type 2 signaling in prurigo nodularis.
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
How should clinicians redefine severe alopecia areata? When is it appropriate to treat ≤20% scalp involvement with oral JAK inhibitors? This expert-level quiz explores remission durability, treatment withdrawal, and practical strategies for...
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Explore the relationship between allergic disease trends, genetic timelines, and the clinical framework used to describe the progression of atopic conditions across childhood.
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
Assess your understanding of early skin barrier interventions in infants and the clinical rationale for prompt treatment of atopic dermatitis in young children, including implications for long-term disease outcomes.
2. Which of the following is associated with this condition? 
1. This antinuclear antibody (ANA) is most characteristic of:
2. Which of the following is associated with this condition?
